Nov 20, 2020

Medscape has launched the latest educational activity in their “Clinical  Advances in Gene Therapy for Hemophilia” series, which is presented through a collaboration between Medscape and the National Hemophilia Foundation. “Updates on Gene Therapy for Hemophilia: The Latest Data and What They Could Mean for Patient Care,” is intended for hematologists, pediatricians, and primary care clinicians, nurses and other healthcare professionals that care for patients with hemophilia. The activity is supported by an independent educational grant from BioMarin, uniQure, and Spark Therapeutics.

Participants who complete the activity will:

  • Have increased knowledge regarding the
    • Key clinical trial data for gene therapy technologies in development
    • Long-term monitoring needs for gene therapy technologies

Updates on Gene Therapy for Hemophilia: The Latest Data and What They Could Mean for Patient Care

Authors: Steven Pipe, MD; David Lillicrap, MD

CME / ABIM MOC / CE Released: 11/17/2020

Valid for credit through: 11/17/2021

If you are already registered with Medscape follow this link to “Updates on Gene Therapy for Hemophilia: The Latest Data and What They Could Mean for Patient Care.”

Access this link to visit the “Clinical Advances in Gene Therapy for Hemophilia” homepage.

If you are not already registered, go to Medscape.org where registration is straightforward and free of charge.